國瓷材料(300285.SZ):深圳愛爾創口腔技術決定使用35萬美元在美國洛杉磯設子公司
格隆匯5月14日丨國瓷材料(300285.SZ)公佈,根據公司的發展戰略及市場需求等狀況,公司的全資孫公司深圳愛爾創口腔技術有限公司(“深圳愛爾創口腔技術”)經過審慎考慮,決定使用自有資金35萬美元在美國洛杉磯投資設立全資子公司,旨在進一步拓展北美市場,以美國子公司為銷售及售後技術服務的平台,為客户提供更為優質、快捷的產品及服務,增強公司國際綜合競爭力。
成立美國子公司將會提升公司在北美的產品供貨速度和效率,更好地滿足客户定製化需求,提供更優質的產品及服務,進而擴大公司在北美的業務範圍及規模,增加公司的銷售收入,提高公司整體業績和盈利水平,增強公司在國際市場的競爭力和影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.